Filtered By:
Source: Circulation
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 235 results found since Jan 2013.
Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results from the CABANA Trial
Conclusions: We found age-based variations in clinical outcomes for catheter ablation compared with drug therapy, with the largest relative and absolute benefits of catheter ablation in younger patients. No prognostic benefits for ablation were seen in the oldest patients. No differences were found by age in treatment-related complications or in the relative effectiveness of catheter ablation in preventing recurrent atrial arrhythmias.PMID:34933570 | DOI:10.1161/CIRCULATIONAHA.121.055297
Source: Circulation - December 22, 2021 Category: Cardiology Authors: Tristram D Bahnson Anna Giczewska Daniel B Mark Andrea M Russo Kristi H Monahan Hussein R Al-Khalidi Adam P Silverstein Jeanne E Poole Kerry L Lee Douglas Packer Source Type: research
Embolic Stroke of Undetermined Source: Can We Identify Subgroups With High Risk for Atrial Fibrillation Who May Benefit From Oral Anticoagulation?
Circulation. 2021 Nov 30;144(22):1747-1749. doi: 10.1161/CIRCULATIONAHA.121.057615. Epub 2021 Nov 29.NO ABSTRACTPMID:34843395 | DOI:10.1161/CIRCULATIONAHA.121.057615
Source: Circulation - November 29, 2021 Category: Cardiology Authors: Graeme J Hankey Source Type: research
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research
Predictors of Development of Atrial Fibrillation in Patients With Embolic Stroke Of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial
Conclusions: Besides age as the most important variable, several other factors, including hypertension, higher body mass index, and lack of diabetes, are independent predictors of AF after ESUS. When baseline NT-proBNP was available, only older age and elevation of this biomarker were predictive of subsequent AF. Understanding who is at higher risk of developing AF will assist in identifying patients who may benefit from more intense, long-term cardiac monitoring.PMID:34649459 | DOI:10.1161/CIRCULATIONAHA.121.055176
Source: Circulation - October 15, 2021 Category: Cardiology Authors: Maria Cecilia Bahit Ralph L Sacco J Donald Easton Juliane Meyerhoff Lisa Cronin Eva Kleine Claudia Grauer Martina Brueckmann Hans-Christoph Diener Renato D Lopes Michael Brainin Philippe Lyrer Rolf Wachter Tomas Segura Christopher B Granger Source Type: research
Amplatzer ™ amulet™ left atrial appendage occluder versus watchman™ device for stroke prophylaxis (amulet ide): a randomized controlled trial
Conclusions: The Amulet occluder was non-inferior for safety and effectiveness of stroke prevention for NVAF compared with the Watchman device, and superior for LAA occlusion. Procedure-related complications were higher with the Amulet device and decreased with operator experience. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02879448.PMID:34459659 | DOI:10.1161/CIRCULATIONAHA.121.057063
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Dhanunjaya Lakkireddy David Thaler Christopher R Ellis Vijendra Swarup Lars Sondergaard John Carroll Michael R Gold James Hermiller Hans-Christoph Diener Boris Schmidt Lee MacDonald Moussa Mansour Brijeshwar Maini Laura O'Brien Stephan Windecker Amulet ID Source Type: research
Amplatzer ™ amulet™ left atrial appendage occluder versus watchman™ device for stroke prophylaxis (amulet ide): a randomized controlled trial
Conclusions: The Amulet occluder was non-inferior for safety and effectiveness of stroke prevention for NVAF compared with the Watchman device, and superior for LAA occlusion. Procedure-related complications were higher with the Amulet device and decreased with operator experience. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02879448.PMID:34459659 | DOI:10.1161/CIRCULATIONAHA.121.057063
Source: Circulation - August 30, 2021 Category: Cardiology Authors: Dhanunjaya Lakkireddy David Thaler Christopher R Ellis Vijendra Swarup Lars Sondergaard John Carroll Michael R Gold James Hermiller Hans-Christoph Diener Boris Schmidt Lee MacDonald Moussa Mansour Brijeshwar Maini Laura O'Brien Stephan Windecker Amulet ID Source Type: research
